Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib, Open Label, Single Center Study of Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

NCT03601819 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT03601819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03601819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib, Open Label, Single Center Study of Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
May 15, 2019
Completion date
July 17, 2020
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, lymphoma, t-cell, cutaneous, lymphoma, t-cell, peripheral, lymphoplasmacytic lymphoma, lymphoproliferative disorders, mantle cell lymphoma, waldenstrom macroglobulinemia